OCT 2024
Immunogenicity & Bioassay Event
We are pleased to announce that Immuni T will be attending the 16th annual Immunogenicity Bioassay summit, taking place in Washington , D.C. from October 15 to 18, 2024.
APR 2024
RENEWAL OF GOOD LABORATORY PRACTICE (GLP) RECOGNITION BY SCC
Immuni T is recognized again as a GLP regulated laboratory by SCC and proudly able to continue collaborating with clients on their valuable studies.
JUL 2021
GOOD LABORATORY PRACTICE (GLP) RECOGNITION
Immuni T is proud to announce that we have been recognized by the Standards Council of Canada (SCC) as being compliant with the OECD Principles of Good Laboratory Practice (GLP). GLP regulates the conduct of all non-clinical safety studies worldwide; the SCC is the only monitoring body that grants GLP recognition in Canada.
GLP recognition means that Immuni T has the infrastructure, personnel, and knowledge to conduct studies that produce valid and high quality data intended for submission to Health Canada, the US FDA, and regulatory bodies around the world (IND or CTA). In the drug development process, these bodies use this data to decide whether clinical studies in humans can proceed.
Immuni T develops, validates, and executes GLP-compliant toxicity, anti-drug antibody (ADA), and other assays, to support non-clinical safety studies.
